Porcine bone marrow stromal cell differentiation on heparin-adsorbed poly(e-caprolactone)–tricalcium phosphate–collagen scaffolds
Source abstract
Abstract
We evaluate the potential of heparin as a substrate component for the fabrication of bone tissue engineering constructs using poly(e-caprolactone)-tricalcium phosphate-collagen type I (PCL-TCP-Col) three-dimensional (3-D) scaffolds. First we explored the ability of porcine bone marrow precursor cells (MPCs) to differentiate down both the adipogenic and osteogenic pathways within 2-D culture systems, with positive results confirmed by Oil-Red-O and Alizarin Red staining, respectively. Secondly, we examined the influence of heparin on the interaction and behaviour of MPCs when seeded onto PCL-TCP-Col 3-D scaffolds, followed by their induction into the osteogenic lineage. Our 3-D findings suggest that cell metabolism and proliferation increased between days 1 and 14, with deposition of extracellular matrix also observed up to 28 days. However, no noticeable difference could be detected in the extent of osteogenesis for PCL-TCP-Col scaffolds groups with the addition of heparin compared to identical control scaffolds without the addition of heparin.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Electrospun Nanofibers in Biomedical Applications · Bone Tissue Engineering Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (37)
Show source-provided references
1. Balanced regulation of proliferation, growth, differentiation, and degradation in skeletal cells10.1196/annals.1402.029 ↗
2. The osteoblast-heparan sulfate axis: control of the bone cell lineage10.1016/j.biocel.2005.03.006 ↗
3. Heparan sulfate regulation of progenitor cell fate10.1002/jcb.20936 ↗
4. Carbohydrates in therapeutics10.2174/187152507781058663 ↗
5. Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: an in vitro investigation10.1177/107602960200800309 ↗
6. Kinetic and structural studies on interactions between heparin or heparan sulfate and proteins of the hedgehog signaling pathway10.1021/bi6025424 ↗
7. Drug-induced osteoporosis10.3949/ccjm.56.3.297 ↗
8. Heparin-induced spinal fractures10.1001/jama.241.22.2417 ↗
9. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism10.1159/000073848 ↗
10. Heparin synergistically enhances interleukin-11 signaling through up-regulation of the MAPK pathway10.1074/jbc.M600169200 ↗
11. Low doses and high doses of heparin have different effects on osteoblast-like Saos-2 cells in vitro10.1002/jcb.20007 ↗
12. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine10.1002/jcp.21200 ↗
13. Engineering of bone tissue with porcine bone marrow stem cells in three-dimensional trabecular metal: in vitro and in vivo studies
14. Porcine mesenchymal stem cells10.1007/s00441-002-0525-z ↗
15. Evaluation of the growth of chondrocytes and osteoblasts seeded into precision scaffolds fabricated by fused deposition manufacturing10.1002/jbm.b.30626 ↗
16. Fabrication and characterisation of scaffolds via solid free form fabrication techniques
17. Combined marrow stromal cell-sheet techniques and high-strength biodegradable composite scaffolds for engineered functional bone grafts10.1016/j.biomaterials.2006.09.032 ↗
18. Protein-heparin interactions measured by BIAcore 2000 are affected by the method of heparin immobilization10.1016/S0003-2697(02)00396-2 ↗
19. Type I collagen-induced osteoblastic differentiation of bone-marrow cells mediated by collagen-alpha2beta1 integrin interaction10.1002/1097-4652(200008)184:2<207::AID-JCP8>3.0.CO;2-U ↗
20. Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides10.1016/S0960-9822(00)80060-3 ↗
21. Heparan sulfate: decoding a dynamic multifunctional cell regulator10.1016/S0962-8924(00)01897-3 ↗
22. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome10.1073/pnas.121183798 ↗
23. Evolution of the Fgf and Fgfr gene families10.1016/j.tig.2004.08.007 ↗
24. FGF signaling in skeletal development10.2741/A321 ↗
25. FGF signaling in the developing endochondral skeleton10.1016/j.cytogfr.2005.02.003 ↗
26. A model for the pharmacological treatment of crouzon syndrome10.1227/01.NEU.0000224323.53866.1E ↗
27. FGFs, heparan sulfate and FGFRs: complex interactions essential for development10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M ↗
28. Heparin protects basic and acidic FGF from inactivation10.1002/jcp.1041280317 ↗
29. Basic fibroblast growth factor (bFGF) dissociates rapidly from heparan sulfates but slowly from receptors
30. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation10.1126/science.1646484 ↗
31. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor10.1016/0092-8674(91)90512-W ↗
32. Heparan sulfate is required for bone morphogenetic protein-7 signaling10.1016/S0006-291X(03)01500-6 ↗
33. Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF10.1073/pnas.91.25.12173 ↗
34. Glycosaminoglycans can modulate extracellular localization of the wingless protein and promote signal transduction10.1083/jcb.135.3.819 ↗
35. Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity10.1074/jbc.270.28.16871 ↗
36. Dynamic biosynthesis of heparan sulphate sequences in developing mouse brain: a potential regulatory mechanism during development10.1042/bst0290177 ↗
37. In vitro biocompatibility and bioactivity of microencapsulated heparan sulfate10.1016/j.biomaterials.2007.01.002 ↗